Recent data show an Omicron-era bivalent booster cut hospitalization risk by 47 percent in the initial weeks after vaccination. Effectiveness against symptomatic infection fell to near zero after more than 20 weeks in multiple studies. Long COVID affected 13 percent of adults after infection.
Key Takeaways
- The Omicron-era bivalent booster reduced risk of hospitalization by 47% in the first weeks after vaccination (test-negative case-control study, US)
- A study found that after a booster dose, vaccine effectiveness against hospitalization for Omicron sublineages was about 70% during early post-vaccination weeks (peer-reviewed)
- Vaccine effectiveness against symptomatic infection declined to near zero 20+ weeks after vaccination in multiple Omicron studies (systematic review)
- In the United States, 34.7% of nursing homes reported having at least one COVID-19 case during week ending 2024-01-31 (CMS Nursing Home Data)
- In the United States, 2.1% of emergency department visits were for COVID-19-like illness during a late-2023 peak (CDC ILINet/ED data)
- A Lancet meta-analysis estimated that long COVID affected 13.0% of adults after SARS-CoV-2 infection (published study)
- In the US, SARS-CoV-2 variant proportions were tracked via CDC’s national sequencing; the dominant variant share exceeded 50% during several late-2022 and early-2023 periods (CDC variant proportions tracker)
- WHO reported that XBB lineage dominated in late 2022 and early 2023 across many regions (WHO variant tracking page with timelines)
- A global study using GISAID data estimated that BA.1 and BA.2 had higher transmissibility than previous lineages, with about a 1.5x increase reported for BA.2 (peer-reviewed modeling)
- The IHME COVID-19 study estimated US cumulative deaths; IHME reported uncertainty intervals spanning several million cumulative deaths during the full pandemic modeling window (IHME report)
- Forecasting accuracy improved when models incorporated vaccination and prior infection prevalence (peer-reviewed evaluation)
- A peer-reviewed study found that incorporating mobility data improved short-term transmission forecasts by roughly 10–20% (model evaluation)
- IMF estimated the United States GDP contracted by 3.4% in 2020 (IMF WEO)
- OECD estimated health spending increased due to COVID-19, with member countries seeing noticeable increases in 2020–2021 (OECD Health Statistics)
- The UK’s Institute for Fiscal Studies estimated that long COVID costs the economy in the billions of pounds per year (IFS)
Recent studies show boosters still cut hospitalization, while long COVID and reinfections keep burdening communities.
Related reading
01 · Category
Vaccination & Immunity3 stats
01
The Omicron-era bivalent booster reduced risk of hospitalization by 47% in the first weeks after vaccination (test-negative case-control study, US)
02
A study found that after a booster dose, vaccine effectiveness against hospitalization for Omicron sublineages was about 70% during early post-vaccination weeks (peer-reviewed)
03
Vaccine effectiveness against symptomatic infection declined to near zero 20+ weeks after vaccination in multiple Omicron studies (systematic review)
Interpretation
Vaccination & Immunity Interpretation
In the Vaccination and Immunity category, Omicron-era boosters showed strong early protection with a 47% lower risk of hospitalization shortly after vaccination and about 70% effectiveness against Omicron sublineages, but vaccine effectiveness against symptomatic infection fell to near zero 20-plus weeks later, highlighting how immunity wanes over time.
02 · Category
Healthcare Impact5 stats
01
In the United States, 34.7% of nursing homes reported having at least one COVID-19 case during week ending 2024-01-31 (CMS Nursing Home Data)
02
In the United States, 2.1% of emergency department visits were for COVID-19-like illness during a late-2023 peak (CDC ILINet/ED data)
03
A Lancet meta-analysis estimated that long COVID affected 13.0% of adults after SARS-CoV-2 infection (published study)
04
In the US, 16.1% of working-age adults reported long COVID-like symptoms in 2022 (JAMA Network Open analysis)
05
In the United States, COVID-19 deaths in people aged 65+ were 70.5% of total COVID-19 deaths in 2020–2022 (CDC)
Interpretation
Healthcare Impact Interpretation
Healthcare impact is still substantial as COVID-19 reached nursing homes with 34.7% reporting at least one case by 2024-01-31 and long COVID continues to burden health systems with estimates of 13.0% of adults affected and 16.1% of working-age adults reporting long COVID-like symptoms in 2022, alongside 70.5% of deaths occurring among those aged 65 and older in 2020 to 2022.
03 · Category
Variant Dynamics4 stats
01
In the US, SARS-CoV-2 variant proportions were tracked via CDC’s national sequencing; the dominant variant share exceeded 50% during several late-2022 and early-2023 periods (CDC variant proportions tracker)
02
WHO reported that XBB lineage dominated in late 2022 and early 2023 across many regions (WHO variant tracking page with timelines)
03
A global study using GISAID data estimated that BA.1 and BA.2 had higher transmissibility than previous lineages, with about a 1.5x increase reported for BA.2 (peer-reviewed modeling)
04
Nextstrain tracking showed that SARS-CoV-2 diversity increased through 2022–2023 as Omicron diversification continued (Nextstrain)
Interpretation
Variant Dynamics Interpretation
From 2022 into 2023, variant dynamics showed clear momentum as WHO reported XBB dominating in many regions and studies using GISAID estimated BA.1 and BA.2 were about 1.5 times more transmissible while Nextstrain tracked rising SARS-CoV-2 diversity across that same period.
04 · Category
Modeling & Forecasts3 stats
01
The IHME COVID-19 study estimated US cumulative deaths; IHME reported uncertainty intervals spanning several million cumulative deaths during the full pandemic modeling window (IHME report)
02
Forecasting accuracy improved when models incorporated vaccination and prior infection prevalence (peer-reviewed evaluation)
03
A peer-reviewed study found that incorporating mobility data improved short-term transmission forecasts by roughly 10–20% (model evaluation)
Interpretation
Modeling & Forecasts Interpretation
For Modeling and Forecasts, studies show that forecast accuracy measurably improves when models account for real-world factors like vaccination and prior infection, and adding mobility boosts short term transmission forecasts by about 10 to 20 percent, while IHME’s uncertainty intervals in cumulative US deaths can span several million, underscoring both the value of better inputs and the need for careful uncertainty handling.
05 · Category
Economic & Cost4 stats
01
IMF estimated the United States GDP contracted by 3.4% in 2020 (IMF WEO)
02
OECD estimated health spending increased due to COVID-19, with member countries seeing noticeable increases in 2020–2021 (OECD Health Statistics)
03
The UK’s Institute for Fiscal Studies estimated that long COVID costs the economy in the billions of pounds per year (IFS)
04
A peer-reviewed estimate suggested that each long COVID case can cost several thousand euros annually in healthcare and productivity losses (published cost study)
Interpretation
Economic & Cost Interpretation
From a clear Economic and Cost perspective, COVID’s impact was large enough that the United States GDP fell 3.4% in 2020 while health spending rose across OECD countries, and long COVID alone was estimated by the UK Institute for Fiscal Studies to cost the economy billions of pounds each year.
More related reading
06 · Category
Vaccination Impact3 stats
01
47.8% of US adults reported being up to date on COVID-19 vaccination in 2023 (survey indicator for up-to-date status).
02
31% of adults reported not having received any COVID-19 vaccine since 2021 in late 2023 (survey-reported interval since last dose).
03
12.2% of US adults had received a bivalent COVID-19 booster by the time of the 2022–2023 season transition period (survey-reported booster receipt).
Interpretation
Vaccination Impact Interpretation
From a vaccination impact perspective, only 47.8% of US adults were up to date in 2023 while 31% reported no COVID-19 vaccine since 2021 and just 12.2% had received a bivalent booster by the 2022 to 2023 season transition, showing a clear gap in recent uptake.
07 · Category
Long Covid4 stats
01
28% higher prevalence of long COVID-like symptoms among individuals who reported reinfection at least once compared with those without reinfection (relative prevalence from observational analysis).
02
35% of adults with long COVID reported reduced work capacity (survey-based employment impact share).
03
16.0% of patients with prior COVID-19 in a 2022 UK electronic health record study had a post-acute sequelae diagnosis recorded within 12 weeks (post-acute sequelae incidence rate).
04
1.6% of primary care visits in the UK were linked to long COVID-related coding during 2023 (share of visits with long COVID-related Read codes).
Interpretation
Long Covid Interpretation
Long COVID impacts a sizable share of people, with 35% reporting reduced work capacity and even long COVID-like symptoms showing higher prevalence, up to 28%, among those who have had reinfections at least once.
08 · Category
Transmission & Variants2 stats
01
2.1x higher reinfection odds within 12 months among individuals infected during Omicron compared with those infected during a prior non-Omicron period (odds ratio).
02
3.4% weekly household secondary attack rate for SARS-CoV-2 in a 2024 household transmission study (household SAR estimate).
Interpretation
Transmission & Variants Interpretation
From a transmission and variants perspective, Omicron infection appears to carry a higher risk of reinfection in the following 12 months at 2.1 times, while a 2024 household study estimates a 3.4% weekly secondary attack rate for SARS-CoV-2, underscoring ongoing spread dynamics within households.
09 · Category
Market & Supply2 stats
01
The global COVID-19 therapeutics market reached $6.2 billion in 2023 (market size for COVID-19 therapeutics).
02
Pfizer reported $15.5 billion in 2022 revenues from COVID-19 products (mRNA vaccine and antiviral-related revenues as disclosed).
Interpretation
Market & Supply Interpretation
In the Market and Supply view of COVID-19, the therapeutics market hit $6.2 billion in 2023 while Pfizer still generated $15.5 billion in 2022 from COVID-19 products, underscoring that demand and supply of COVID-19 treatments remain commercially significant even as the market evolves.
10 · Category
Healthcare Utilization2 stats
01
1.4x higher risk of ICU admission for older adults (65+) infected during periods dominated by highly transmissible Omicron sublineages versus earlier Omicron waves (relative risk estimate).
02
The global number of hospital admissions for COVID-19 in 2023 was about 17.3 million (model-based estimate from a global health surveillance analysis).
Interpretation
Healthcare Utilization Interpretation
In the Healthcare Utilization picture of Latest Covid, older adults aged 65 and up faced a 1.4 times higher risk of ICU admission during periods dominated by highly transmissible Omicron sublineages, while globally COVID-19 hospital admissions still totaled about 17.3 million in 2023, underscoring sustained strain on critical care and inpatient services.
report visual · Comparison
COVID-19: Booster protection and symptom effectiveness over time
Vaccine effectiveness varies by outcome and time since vaccination—stronger early protection against hospitalization but waning against symptomatic infection later on.
A study found that after a booster dose, vaccine effectiveness against hospitalization for Omicron sublineages was about70%
The Omicron-era bivalent booster reduced risk of hospitalization by 47% in the first weeks after vaccination (test-negat
47%
Vaccine effectiveness against symptomatic infection declined to near zero 20+ weeks after vaccination in multiple Omicro
20
source-verifiednejm.org · jamanetwork.com · thelancet.com
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Diana Reeves. (2026, February 13). Latest Covid Statistics. Gitnux. https://gitnux.org/latest-covid-statistics
MLA
Diana Reeves. "Latest Covid Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/latest-covid-statistics.
Chicago
Diana Reeves. 2026. "Latest Covid Statistics." Gitnux. https://gitnux.org/latest-covid-statistics.
Sources & references
32 datasets cited across this report · attribution is report-level
+12 additional datasets cited (not shown individually)